- Report
- March 2025
- 191 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- January 2025
- 120 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 194 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- September 2024
- 133 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- March 2025
- 193 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- October 2023
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2021
- 178 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- February 2024
- 100 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- October 2023
- 181 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- November 2023
- 198 Pages
Global
€4749EUR$4,995USD£3,989GBP
The Human Liver Model market is a subset of the Clinical Trials market, focused on the development of in vitro models of the human liver. These models are used to study the effects of drugs and other compounds on the liver, and to predict the safety and efficacy of drugs in humans. The models are typically composed of human liver cells, and can be used to study the metabolism, toxicity, and pharmacokinetics of drugs. The models are also used to study the effects of genetic and environmental factors on the liver.
The Human Liver Model market is growing due to the increasing demand for in vitro models for drug development and safety testing. The models are also being used to study the effects of diseases on the liver, such as hepatitis and cirrhosis.
Companies in the Human Liver Model market include InSphero, Hepregen, and Emulate. Show Less Read more
